US stocks surge | Eli Lilly (LLY.US) hits new high again, up over 14% this year

Wisdom Financial App learned that on Monday, Eli Lilly (LLY.US) continued to rise by more than 1%, following a 7% surge in the previous trading day, with the stock price reaching a new high of $1238, up over 14% since the beginning of the year. In terms of news, Eli Lilly previously announced that its new drug Jaypirca for the treatment of chronic lymphocytic leukemia received a positive recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency, and it is expected that the European Union will make a formal approval decision in the next one to two months. Additionally, the company's other new drug Onswik also received a positive recommendation for market approval from the European Medicines Agency. Furthermore, Wall Street investment bank Leerink Partners has raised Eli Lilly's target stock price from $1119 to $1232 and maintains an "outperform" rating.